DexCom, Inc. (DXCM)
DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom shares fall on slow revenue growth
Dexcom shares fell on Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earlier, according to a release.
Dexcom beats estimates for third-quarter sales, reiterates annual forecast
Medical device maker Dexcom beat Wall Street estimates for third-quarter revenue on Thursday, helped by resilient demand for its continuous glucose monitors for diabetes patients.
Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?
DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - DXCM
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Stay Ahead of the Game With DexCom (DXCM) Q3 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top -and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - DXCM
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit - DXCM
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
FINAL DXCM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds DexCom, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between April 28, 2023, and July 25, 2024, inclusive (the "Class Period").
